Happy to discuss the Company Footmax, I recall you recently...

Happy to discuss the Company Footmax, I recall you recently making a discussion point of the latest signed distributions....

11 July 2019 - June Quarterly Report

Strategic Distribution Agreements Signed

During the quarter, the Company signed an impressive five Pharma distribution agreements...

MGC Pharma also terminated its supply agreement with NUBU NZ during the quarter, due to NUBU NZ not meeting their contractual terms of the agreement
https://www.asx.com.au/asxpdf/20190711/pdf/446jwmskx4k6sg.pdf

1 April 2019 - CannaTech Conference Presentation - Tel Aviv 2019

Supply agreement with NUBU Pharmaceuticals, a New Zealand based company, to supply MGC products into pharmacies, hospitals and universities throughout the country. This agreement provides a clear pathway for the delivery of the first MGC pharmaceutical products to patients via NUBU Pharma’s partner Pro Pharma and its relationship with over 250 pharmacists in New Zealand
https://www.asx.com.au/asxpdf/20190401/pdf/443y5hd7qjysp5.pdf

Oct 2018 - NUBU Pharmaceuticals and MGC announce exclusive distribution agreement

The exclusive agreement was announced at the global cannabis conference, CannaTech, held in Sydney today...

https://www.nubupharma.com/post/manage-your-blog-from-your-live-site (Can't find ASX ann. - don't recall there being one.)

30 July 2018 - June Quarterly Activity and Cashflow Report

Supply Agreement Signed with New Zealand Distributor

MXC signed a supply agreement with MW Pharma during the quarter, a New Zealand based medicinal cannabis distributor to distribute its current and future pharma grade medical cannabis products into pharmacies, hospitals and universities throughout the country. MW Pharma are responsible for obtaining all necessary permits and licenses for the export and sale of MXC’s products. This agreement provides a clear pathway for the delivery of the of first MGC’s pharmaceutical products to patients via MW Pharma’s partner Pro Pharma and its relationship with over 250 pharmacists in New Zealand. This will increase the strength of the Company’s position and distribution networks within the Australasian markets. The agreement also has the potential to deliver revenue at high gross profit margins as the Company plans to commence manufacturing of the products at its GMP certified Slovenian facility.
https://www.asx.com.au/asxpdf/20180730/pdf/43wwdzqw2j09p4.pdf

If we're to note that the NUBU / Pro Pharma agreement, according to the company, was to provide a clear pathway at the start of the very same quarter the agreement was terminated by the company, in your opinion Footmax, what percentage of "signed" distribution deals could lapse to termination? or if you prefer, what percentage could come to fruition?